Company through its co-development partner, Giiant Pharma, Inc. ("Giiant"), receives funding from Canadian Scientific Research and Experimental Development (SR&ED) Tax Credit Program for PALI-2108 Ongoing progress of Palisade Bio's Phase 1a/b UC study of PALI-2108 with topline data expected in the first half of 2025 Carlsbad, CA, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade", "Palisade Bio", or the "Company"), a clinical-stage biopharmaceutical company focused on developing ...

Company through its co-development partner, Giiant Pharma, Inc. (“Giiant”), receives funding from Canadian Scientific Research and Experimental Development (SR&ED) Tax Credit Program for PALI-2108 Ongoing progress of Palisade Bio’s Phase 1a/b UC study of PALI-2108 with topline data expected in the first half of 2025 Carlsbad, CA, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing ...

On-demand video webcast now available here Carlsbad, CA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced it participated in the Virtual Investor "Top 5 for ‘25” On-Demand Conference. As part of the event, JD Finley, Chief Executive Officer of Palisade Bio ...

Summary of Palisade Bio (PALI) Conference Call - February 19, 2025 Company Overview - **Company**: Palisade Bio (PALI) - **Industry**: Biotechnology, specifically focusing on treatments for inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn's disease Core Points and Arguments 1. **Drug Development**: - PALI-2108 is a PDE4 inhibitor formulated as a prodrug, originally developed in Merck labs, designed to be more potent than previous inhibitors for treating ulcerative colitis and Crohn's disease [3][4] - The prodrug formulation minimizes systemic exposure, allowing the drug to reach the distal ileum in the colon, targeting the disease more effectively [4] 2. **Market Opportunity**: - Nearly 1 million patients in the U.S. suffer from ulcerative colitis, with 55% experiencing moderate to severe cases [5] - Current treatments have less than a 20% success rate and often come with poor safety profiles, highlighting the need for better options [5] 3. **Phase One Study Results**: - Preliminary data from the single ascending dose (SAD) study showed that PALI-2108 was well tolerated across all doses (15 mg to 450 mg) with no serious adverse events or treatment-related laboratory abnormalities [6] - Mild treatment-emergent adverse events were noted only at the highest dose, indicating a favorable safety profile [6] 4. **Market Size and Deal Activity**: - The global ulcerative colitis market is currently valued at over $7 billion and is projected to exceed $9 billion by 2028 [7] - There have been 70 deals in the IBD space over the last five years, with an average deal value of $1.2 billion, indicating strong investor interest and potential for growth [7][8] 5. **Second Drug Development**: - PALI-1908, another drug in development, utilizes the same active PDE4 inhibitor as PALI-2108 but is designed to release the drug in the terminal ileum, targeting fibrosis in Crohn's patients [9] - Initial data suggests that PALI-2108 may also be effective for treating fibrotic Crohn's disease, potentially reducing the need for a separate drug development process [9] Additional Important Information - The company emphasizes the importance of oral delivery for patient compliance and preference, which is a significant advantage over current treatment options [4] - The favorable safety profile and targeted delivery mechanism of PALI-2108 are expected to provide a competitive edge in the market [6][7] - The company plans to provide further updates on the development of PALI-2108 and its potential applications in treating Crohn's disease in the coming months [9]

Data presented at the 2025 Crohn’s and Colitis Congress PALI-2108 demonstrated to effectively reduce colitis symptoms in DSS mouse model without CNS toxicity associated with systemic exposure Company advancing Phase 1a/b study of PALI-2108 and has demonstrated a favorable safety profile in single-ascending-dose cohorts Carlsbad, CA, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on devel ...

Core Insights - Palisade Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases [3] Group 1: Presentation Announcement - Palisade Bio announced that its abstract has been accepted for poster presentation at the Crohn's & Colitis Congress scheduled for February 6-8, 2025, in San Francisco, CA [1] - The poster presentation will focus on PALI-2108, a colon-specific PDE4B inhibitor prodrug that is activated in the colon and reduces ulcerative colitis symptoms in an acute colitis DSS mouse model [2] Group 2: Presentation Details - The poster session will take place on February 7, 2025, from 5:00 PM to 6:30 PM PST at the Exhibition Hall, Level 1, Moscone West [2] - For further information about the congress, interested parties can visit crohnscolitiscongress.org [2]

Core Insights - Palisade Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases [3] Group 1: Presentation Announcement - Palisade Bio announced that its abstract has been accepted for poster presentation at the Crohn's & Colitis Congress scheduled for February 6-8, 2025, in San Francisco, CA [1] - The poster presentation will focus on PALI-2108, a colon-specific PDE4B inhibitor prodrug that is activated in the colon and reduces ulcerative colitis symptoms in an acute colitis DSS mouse model [2] Group 2: Presentation Details - The poster session will take place on February 7, 2025, from 5:00 PM to 6:30 PM PST at the Exhibition Hall, Moscone West [2] - For further information about the congress, interested parties can visit crohnscolitiscongress.org [2]

Live webcast on Wednesday, January 29th at 2:20 PM ET Carlsbad, CA, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that JD Finley, Chief Executive Officer of Palisade will present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar being ...

Company on track to report topline data in first half of 2025 Positive preliminary data from all five single ascending dose (SAD) cohorts ranging from 15mg to 450mg support safety and tolerability of PALI-2108 Continued progress toward Phase 1b/2a of PALI-2108 trial for the treatment of UC Carlsbad, CA, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (NASDAQ:PALI) ("Palisade," "Palisade Bio" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for auto ...

Carlsbad, CA, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it had made an equity grant to a new employee under its 2021 Inducement Plan, as amended. The Company approved the issuance of an option to purchase 2,600 shares of the Company’s common sto ...